Symbols / ARVN
ARVN Chart
About
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 858.68M |
| Enterprise Value | 178.66M | Income | -80.80M | Sales | 262.60M |
| Book/sh | 6.83 | Cash/sh | 10.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | 246 | IPO | — |
| P/E | — | Forward P/E | -3.83 | PEG | — |
| P/S | 3.27 | P/B | 1.96 | P/C | — |
| EV/EBITDA | -1.60 | EV/Sales | 0.68 | Quick Ratio | 4.86 |
| Current Ratio | 4.92 | Debt/Eq | 2.05 | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -3.49 | EPS Growth | — |
| Revenue Growth | -84.00% | Earnings | 2026-04-30 | ROA | -7.94% |
| ROE | -16.23% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -7.55% | Profit Margin | -30.77% | Shs Outstand | 63.96M |
| Shs Float | 55.37M | Short Float | 6.42% | Short Ratio | 5.22 |
| Short Interest | — | 52W High | 14.22 | 52W Low | 5.90 |
| Beta | 1.94 | Avg Volume | 821.42K | Volume | 590.04K |
| Target Price | $14.56 | Recom | Buy | Prev Close | $13.60 |
| Price | $13.37 | Change | -1.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.56
Mean price target
2. Current target
$13.37
Latest analyst target
3. DCF / Fair value
$-25.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.37
Low
$6.00
High
$20.00
Mean
$14.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Citigroup | Buy → Buy | $18 |
| 2026-02-25 | reit | Piper Sandler | Overweight → Overweight | $20 |
| 2026-02-25 | main | Evercore ISI Group | Outperform → Outperform | $19 |
| 2026-02-25 | main | Wedbush | Neutral → Neutral | $11 |
| 2026-01-06 | up | Citigroup | Neutral → Buy | $15 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $18 |
| 2025-11-10 | main | Stephens & Co. | Overweight → Overweight | $15 |
| 2025-11-06 | main | Wells Fargo | Overweight → Overweight | $15 |
| 2025-11-06 | main | Barclays | Overweight → Overweight | $16 |
| 2025-10-30 | main | BTIG | Buy → Buy | $14 |
| 2025-10-15 | down | Goldman Sachs | Neutral → Sell | $6 |
| 2025-09-18 | main | BTIG | Buy → Buy | $10 |
| 2025-09-18 | main | Stephens & Co. | Overweight → Overweight | $14 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-08-07 | main | Wells Fargo | Overweight → Overweight | $16 |
| 2025-08-07 | main | Guggenheim | Buy → Buy | $15 |
| 2025-06-02 | down | Leerink Partners | Outperform → Market Perform | $9 |
| 2025-05-15 | main | UBS | Buy → Buy | $21 |
| 2025-05-09 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $11 |
| 2025-05-05 | main | Citigroup | Neutral → Neutral | $10 |
- Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis ue, 10 Mar 2026 06
- Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat Mon, 09 Mar 2026 20
- Top Arvinas Insider Just Made a Bold Move That Could Turn Heads on Wall Street - TipRanks ue, 10 Mar 2026 03
- How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance Fri, 06 Mar 2026 10
- Discipline and Rules-Based Execution in ARVN Response - Stock Traders Daily Fri, 06 Mar 2026 08
- Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus hu, 05 Mar 2026 19
- Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock - Investing.com Nigeria hu, 19 Feb 2026 08
- $ARVN stock is down 8% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 14
- ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits hu, 12 Feb 2026 17
- Biotech firm Arvinas lines up four investor talks in March - Stock Titan Mon, 23 Feb 2026 08
- Vanguard Group Inc. Trims Position in Arvinas, Inc. $ARVN - MarketBeat Sat, 07 Mar 2026 12
- Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance ue, 24 Feb 2026 08
- Arvinas (NASDAQ:ARVN) Given New $18.00 Price Target at Citigroup - MarketBeat hu, 05 Mar 2026 20
- Insider Sale: Chief Accounting Officer of $ARVN Sells 1,108 Shares - Quiver Quantitative Wed, 25 Feb 2026 22
- Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Yahoo Finance Mon, 02 Mar 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 35297 | 466154 | — | Sale at price 13.14 - 13.24 per share. | HOUSTON JOHN G | Director | — | 2026-02-27 00:00:00 | D |
| 1 | 45000 | — | — | Stock Award(Grant) at price 0.00 per share. | BERKOWITZ NOAH | Officer | — | 2026-02-26 00:00:00 | D |
| 2 | 45000 | — | — | Stock Award(Grant) at price 0.00 per share. | SAIK ANDREW | Chief Financial Officer | — | 2026-02-26 00:00:00 | D |
| 3 | 12420 | — | — | Stock Award(Grant) at price 0.00 per share. | LOOMIS DAVID K | Officer | — | 2026-02-26 00:00:00 | D |
| 4 | 147791 | — | — | Stock Award(Grant) at price 0.00 per share. | TEEL RANDY PH.D. | Chief Executive Officer | — | 2026-02-26 00:00:00 | D |
| 5 | 45000 | — | — | Stock Award(Grant) at price 0.00 per share. | CACACE ANGELA M | Officer | — | 2026-02-26 00:00:00 | D |
| 6 | 1108 | 13473 | — | Sale at price 12.16 per share. | LOOMIS DAVID K | Officer | — | 2026-02-23 00:00:00 | D |
| 7 | 4786 | 58198 | — | Sale at price 12.16 per share. | TEEL RANDY PH.D. | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
| 8 | 3609 | 43885 | — | Sale at price 12.16 per share. | CACACE ANGELA M | Officer | — | 2026-02-23 00:00:00 | D |
| 9 | 5685 | 67595 | — | Sale at price 11.89 per share. | BERKOWITZ NOAH | Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -113.30M | -243.60M | -394.80M | -255.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -80.80M | -198.90M | -367.30M | -282.50M |
| ReconciledDepreciation | 5.20M | 6.60M | 6.70M | 8.20M |
| EBITDA | -113.30M | -243.60M | -394.80M | -255.00M |
| EBIT | -118.50M | -250.20M | -401.50M | -263.20M |
| NetInterestIncome | 38.40M | 54.80M | 38.80M | 12.00M |
| InterestExpense | 100.00K | |||
| InterestIncome | 38.40M | 54.80M | 38.80M | 12.00M |
| NormalizedIncome | -80.80M | -198.90M | -367.30M | -282.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -80.80M | -198.90M | -367.30M | -282.50M |
| TotalExpenses | 381.10M | 513.60M | 480.00M | 394.60M |
| TotalOperatingIncomeAsReported | -118.50M | -250.20M | -401.50M | -263.20M |
| DilutedAverageShares | 71.90M | 55.50M | 53.20M | 50.00M |
| BasicAverageShares | 71.90M | 55.50M | 53.20M | 50.00M |
| DilutedEPS | -2.77 | -6.62 | -5.31 | -3.82 |
| BasicEPS | -2.77 | -6.62 | -5.31 | -3.82 |
| DilutedNIAvailtoComStockholders | -80.80M | -198.90M | -367.30M | -282.50M |
| NetIncomeCommonStockholders | -80.80M | -198.90M | -367.30M | -282.50M |
| NetIncome | -80.80M | -198.90M | -367.30M | -282.50M |
| NetIncomeIncludingNoncontrollingInterests | -80.80M | -198.90M | -367.30M | -282.50M |
| NetIncomeContinuousOperations | -80.80M | -198.90M | -367.30M | -282.50M |
| EarningsFromEquityInterestNetOfTax | 0.00 | 0.00 | -2.50M | -10.60M |
| TaxProvision | 300.00K | 600.00K | 900.00K | 20.90M |
| PretaxIncome | -80.50M | -198.30M | -363.90M | -251.00M |
| OtherIncomeExpense | -400.00K | -2.90M | -1.20M | 200.00K |
| OtherNonOperatingIncomeExpenses | -400.00K | -2.90M | -1.20M | 200.00K |
| EarningsFromEquityInterest | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 38.40M | 54.80M | 38.80M | 12.00M |
| InterestExpenseNonOperating | 100.00K | |||
| InterestIncomeNonOperating | 38.40M | 54.80M | 38.80M | 12.00M |
| OperatingIncome | -118.50M | -250.20M | -401.50M | -263.20M |
| OperatingExpense | 381.10M | 513.60M | 480.00M | 394.60M |
| ResearchAndDevelopment | 285.20M | 348.20M | 379.70M | 315.00M |
| SellingGeneralAndAdministration | 95.90M | 165.40M | 100.30M | 79.60M |
| GeneralAndAdministrativeExpense | 95.90M | 165.40M | 100.30M | 79.60M |
| OtherGandA | 95.90M | 165.40M | 100.30M | 79.60M |
| TotalRevenue | 262.60M | 263.40M | 78.50M | 131.40M |
| OperatingRevenue | 262.60M | 263.40M | 78.50M | 131.40M |
| Line Item | 2025-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 10.00M | 0.00 | ||
| OrdinarySharesNumber | 63.50M | 68.80M | 68.00M | 53.20M |
| ShareIssued | 73.50M | 68.80M | 68.00M | 53.20M |
| TotalDebt | 8.90M | 9.70M | 3.20M | 5.50M |
| TangibleBookValue | 433.80M | 561.60M | 660.00M | 564.90M |
| InvestedCapital | 434.20M | 562.20M | 660.80M | 565.90M |
| WorkingCapital | 558.20M | 837.50M | 1.02B | 945.10M |
| NetTangibleAssets | 433.80M | 561.60M | 660.00M | 564.90M |
| CapitalLeaseObligations | 8.50M | 9.10M | 2.40M | 4.50M |
| CommonStockEquity | 433.80M | 561.60M | 660.00M | 564.90M |
| TotalCapitalization | 434.20M | 562.20M | 660.80M | 565.90M |
| TotalEquityGrossMinorityInterest | 433.80M | 561.60M | 660.00M | 564.90M |
| StockholdersEquity | 433.80M | 561.60M | 660.00M | 564.90M |
| GainsLossesNotAffectingRetainedEarnings | 1.20M | 1.00M | -3.10M | -19.20M |
| OtherEquityAdjustments | 1.20M | 1.00M | -3.10M | -19.20M |
| TreasuryStock | 91.90M | 0.00 | ||
| RetainedEarnings | -1.61B | -1.53B | -1.33B | -965.40M |
| AdditionalPaidInCapital | 2.14B | 2.09B | 2.00B | 1.55B |
| CapitalStock | 0.00 | 0.00 | 100.00K | 100.00K |
| CommonStock | 0.00 | 0.00 | 100.00K | 100.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 284.10M | 529.80M | 644.60M | 703.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 141.60M | 300.00M | 387.50M | 408.80M |
| OtherNonCurrentLiabilities | 100.00K | 100.00K | ||
| NonCurrentDeferredLiabilities | 134.30M | 292.00M | 386.20M | 405.10M |
| NonCurrentDeferredRevenue | 134.30M | 292.00M | 386.20M | 405.10M |
| LongTermDebtAndCapitalLeaseObligation | 7.20M | 7.90M | 1.30M | 3.70M |
| LongTermCapitalLeaseObligation | 6.80M | 7.30M | 500.00K | 2.70M |
| LongTermDebt | 400.00K | 600.00K | 800.00K | 1.00M |
| CurrentLiabilities | 142.50M | 229.80M | 257.10M | 295.10M |
| CurrentDeferredLiabilities | 71.30M | 156.20M | 163.00M | 218.60M |
| CurrentDeferredRevenue | 71.30M | 156.20M | 163.00M | 218.60M |
| CurrentDebtAndCapitalLeaseObligation | 1.70M | 1.80M | 1.90M | 1.80M |
| CurrentCapitalLeaseObligation | 1.70M | 1.80M | 1.90M | 1.80M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 17.50M | 22.40M | 25.70M | 18.70M |
| PayablesAndAccruedExpenses | 52.00M | 49.40M | 66.50M | 56.00M |
| CurrentAccruedExpenses | 22.80M | 32.80M | 48.00M | 40.00M |
| Payables | 29.20M | 16.60M | 18.50M | 16.00M |
| TotalTaxPayable | 4.80M | 3.20M | 700.00K | 10.30M |
| IncomeTaxPayable | 4.80M | 3.20M | 700.00K | 10.30M |
| AccountsPayable | 24.40M | 13.40M | 17.80M | 5.70M |
| TotalAssets | 717.90M | 1.09B | 1.30B | 1.27B |
| TotalNonCurrentAssets | 17.20M | 24.10M | 24.40M | 28.60M |
| OtherNonCurrentAssets | 3.80M | 8.10M | 10.40M | 10.80M |
| NonCurrentAccountsReceivable | 10.80M | 12.50M | ||
| NetPPE | 13.40M | 16.00M | 14.00M | 17.80M |
| AccumulatedDepreciation | -28.20M | -25.60M | -21.10M | -16.60M |
| GrossPPE | 41.60M | 41.60M | 35.10M | 34.40M |
| Leases | 9.10M | 9.30M | 11.50M | 10.90M |
| OtherProperties | 29.50M | 29.60M | 21.00M | 21.50M |
| MachineryFurnitureEquipment | 3.00M | 2.70M | 2.60M | 2.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 700.70M | 1.07B | 1.28B | 1.24B |
| OtherCurrentAssets | 8.90M | 14.20M | 6.50M | 21.40M |
| RestrictedCash | 0.00 | 5.50M | 5.50M | 4.50M |
| PrepaidAssets | 19.70M | |||
| Receivables | 6.40M | 13.70M | 7.20M | 8.00M |
| OtherReceivables | 5.40M | 8.00M | 7.20M | 7.00M |
| AccountsReceivable | 1.00M | 5.70M | 0.00 | 1.00M |
| CashCashEquivalentsAndShortTermInvestments | 685.40M | 1.04B | 1.26B | 1.21B |
| OtherShortTermInvestments | 542.50M | 938.90M | 949.30M | 1.12B |
| CashAndCashEquivalents | 142.90M | 100.50M | 311.70M | 81.30M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -275.70M | -261.10M | -350.70M | -280.30M |
| RepurchaseOfCapitalStock | -91.90M | 0.00 | 0.00 | |
| RepaymentOfDebt | -200.00K | -400.00K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 387.20M | 0.00 |
| CapitalExpenditure | -1.90M | -1.80M | -2.90M | -6.80M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 100.00K | |
| IncomeTaxPaidSupplementalData | 2.30M | 11.10M | 11.10M | 0.00 |
| EndCashPosition | 142.90M | 100.50M | 317.20M | 86.80M |
| BeginningCashPosition | 100.50M | 317.20M | 86.80M | 112.80M |
| ChangesInCash | 42.40M | -216.70M | 230.40M | -26.00M |
| FinancingCashFlow | -91.40M | 7.90M | 374.70M | 4.70M |
| CashFlowFromContinuingFinancingActivities | -91.40M | 7.90M | 374.70M | 4.70M |
| NetOtherFinancingCharges | -17.00M | -4.60M | ||
| ProceedsFromStockOptionExercised | 700.00K | 8.30M | 4.50M | 4.70M |
| NetCommonStockIssuance | -91.90M | 0.00 | 387.20M | 0.00 |
| CommonStockPayments | -91.90M | 0.00 | 0.00 | |
| CommonStockIssuance | 0.00 | 0.00 | 387.20M | 0.00 |
| NetIssuancePaymentsOfDebt | -200.00K | -400.00K | 0.00 | 0.00 |
| NetLongTermDebtIssuance | -200.00K | -400.00K | 0.00 | 0.00 |
| LongTermDebtPayments | -200.00K | -400.00K | 0.00 | 0.00 |
| InvestingCashFlow | 407.60M | 34.70M | 203.50M | 242.80M |
| CashFlowFromContinuingInvestingActivities | 407.60M | 34.70M | 203.50M | 242.80M |
| NetInvestmentPurchaseAndSale | 409.50M | 36.40M | 206.40M | 249.60M |
| SaleOfInvestment | 763.70M | 688.50M | 1.16B | 1.14B |
| PurchaseOfInvestment | -354.20M | -652.10M | -956.30M | -886.40M |
| NetPPEPurchaseAndSale | -1.90M | -1.70M | -2.90M | -6.80M |
| SaleOfPPE | 0.00 | 100.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -1.90M | -1.80M | -2.90M | -6.80M |
| OperatingCashFlow | -273.80M | -259.30M | -347.80M | -273.50M |
| CashFlowFromContinuingOperatingActivities | -273.80M | -259.30M | -347.80M | -273.50M |
| ChangeInWorkingCapital | -233.70M | -140.60M | -44.40M | -82.60M |
| ChangeInOtherWorkingCapital | -242.60M | -101.00M | -74.60M | -116.80M |
| ChangeInOtherCurrentLiabilities | -2.00M | -1.90M | -2.00M | -1.90M |
| ChangeInPayablesAndAccruedExpense | -1.70M | -21.20M | 17.30M | 20.20M |
| ChangeInAccruedExpense | 4.20M | |||
| ChangeInPayable | -1.70M | -21.20M | 17.30M | 20.20M |
| ChangeInAccountPayable | -1.70M | -21.20M | 17.30M | 20.20M |
| ChangeInPrepaidAssets | 5.30M | -7.00M | 14.10M | -1.80M |
| ChangeInReceivables | 7.30M | -9.50M | 800.00K | 17.70M |
| ChangesInAccountReceivables | 4.70M | -5.70M | 1.00M | 14.00M |
| OtherNonCashItems | -8.50M | -17.20M | -15.30M | 7.50M |
| StockBasedCompensation | 44.00M | 88.20M | 71.60M | 75.50M |
| DepreciationAmortizationDepletion | 5.20M | 6.60M | 6.70M | 8.20M |
| DepreciationAndAmortization | 5.20M | 6.60M | 6.70M | 8.20M |
| Depreciation | 5.20M | 6.60M | 6.70M | 8.20M |
| OperatingGainsLosses | 2.60M | 900.00K | 400.00K | -800.00K |
| GainLossOnInvestmentSecurities | 900.00K | 400.00K | 200.00K | |
| GainLossOnSaleOfPPE | 0.00 | 2.60M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -80.80M | -198.90M | -367.30M | -282.50M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARVN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|